[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-st-elevation-acute-coronary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-st-elevation-acute-coronary-syndrome":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100619319","efficacy-of-immediate-versus-staged-complete-revascularization-in-patients-with-nste-acs-and-multivessel-disease-future-ii-100619319",false,"NCT07343076","Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE II)","Inclusion Criteria:\n\n1. Age: 18 years or older.\n2. Patients with intermediate-to-high risk NSTE-ACS who meet the diagnostic criteria specified in current guideline, complicated by multivessel coronary artery disease, and have successfully undergone PCI for the culprit vessel.\n3. PCI within 72 hours of diagnosis.\n4. Accompanied by multivessel disease: defined as at least one non-culprit artery that meets the following conditions: a diameter of ≥2.5 mm by visual inspection, which can be successfully subjected to PCI, and the most severe diameter stenosis rate by visual inspection is at least 70% or positive coronary physiology testing.\n5. Sign an informed consent form before participating in the study.\n\nExclusion Criteria:\n\n1. Have received thrombolytic treatment.\n2. Cardiogenic shock or SBP\\\u003C 90 mmHg.\n3. Patients in whom the culprit vessel cannot be clearly identified.\n4. Left main coronary artery lesion, non-infarct-related arteries are CTO lesions or severely calcified lesions, complex lesions that require the use of special devices such as rotational ablation\u002Flaser.\n5. Previous PCI within the past 1 month or previous coronary artery bypass graft (CABG).\n6. Accompanied by other diseases that lead to an expected survival time of ≤ 12 months.\n7. Patients with other serious diseases such as severe renal insufficiency (creatinine clearance value \\\u003C30ml\u002Fmin), hepatic insufficiency, thrombocytopenia (≤50\\*109\u002FL).\n8. Patients with severe valvular disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, and primary pulmonary hypertension.\n9. Not suitable for clinical study:\n\n   1. Have enrolled in the other clinical studies that may affect the outcome assessment of this study.\n   2. Pregnant and lactating women.\n   3. Known allergy to the drugs that may be used in the study.\n   4. Unable to comply with the trial protocol or follow-up requirements; or the investigator believes that participation in the trial may put the patient at greater risk.","ALL","18 Years",{"count":18,"type":19},1904,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a prospective, multi-center, randomized controlled, open-label, blinded endpoint assessment study. The objective is to compare the 1-year incidence of major adverse cardiovascular and cerebrovascular events (MACCE) between two treatment strategies-immediate complete revascularization and staged complete revascularization-in NSTE-ACS patients with multivessel disease (MVD).\n\nNSTE-ACS patients who meet other the inclusion and exclusion criteria will be randomized into the following two groups after signing an informed consent form:\n\nIntervention group Immediate Complete Revascularization: Emergency PCI for the culprit vessel is performed successfully, and simultaneous PCI is conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing).\n\nControl group During emergency intervention, PCI is performed only on the culprit vessel. Elective PCI is then conducted for non-culprit vessels that meet the defined criteria (visually estimated diameter ≥ 2.5 mm, eligible for successful PCI, and visually estimated maximum diameter stenosis ≥ 70% or positive coronary physiology testing)-either during the current emergency hospitalization or within 6 weeks after the culprit vessel PCI.",[25,26,27,28],"NSTEMI","NSTEMI - Non-ST Segment Elevation MI","Non-ST-elevation Acute Coronary Syndrome","NSTE-ACS (NSTEMI and UA)",[25,30],"FUTURE II","NOT_YET_RECRUITING","2026-01-28",{"date":34,"type":35},"2026-01-30","ACTUAL",{"date":37,"type":19},"2026-02-28",{"date":39,"type":19},"2031-02-28",{"name":41,"class":42},"RenJi Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100549597","japanese-coronary-intervention-using-drug-eluting-and-perfusion-therapy-for-left-main-disease-jdepth-lm-registry-100549597","NCT06436092","Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patient with stable coronary artery disease, non-ST-elevation myocardial infarction, or unstable angina\n3. Left main disease confirmed by coronary angiography or coronary CT angiography\n4. Clinical and anatomical eligibility for PCI as agreed by the local Heart Team\n5. Patient with consent prior to undergoing PCI\n6. Left main Medina classification (1,1,1), (1,0,1), (0,1,1), (0,0,1) confirmed by coronary angiography\n7. De novo target lesion in LMT-LAD amenable for crossover stenting with provisional side-branch approach as determined by PCI operator\n8. De novo ostial LCx lesions\n9. Lesion indicated in No. 8 with a length of less than 10 mm or a stenosis of less than 70% confirmed by coronary angiography\n\nExclusion Criteria:\n\n1. Inability to provide written informed consent\n2. Patient with a history of ST-elevation myocardial infarction within the previous 1 week\n3. Patient in a state of cardiogenic shock\n4. Patient with a history of coronary artery bypass grafting\n5. Patient with malignant tumors or other conditions with a life expectancy of less than one year\n6. Patient considered suitable for stent placement in the ostial LCx from a medical perspective\n7. Patient considered unsuitable for anti-thrombotic therapy after PCI\n8. Other patient whom the investigator deems unsuitable for the safe conduct of LM-PCI, including W-KBT",{"count":50,"type":19},280,"12 Months","OBSERVATIONAL","JDEPTH-LM Registry is a prospective, observational, multi-center study designed for the efficacy and safety of Double-effect kissing balloon technique (W-KBT) in left main (LM) bifurcation percutaneous coronary intervention (PCI) using Perfusion balloon (PB) and Drug coated balloon (DCB) in patients with left main coronary artery disease (LMD) with left circumflex artery (LCx) ostium stenosis.",[55,27,56],"Stable Angina","Unstable Angina",[58],"Ischemic heart disease","RECRUITING","2025-03-11",{"date":62,"type":35},"2025-03-13",{"date":64,"type":35},"2024-05-27",{"date":66,"type":19},"2029-12-31",{"name":68,"class":69},"TCROSS Co., Ltd.","INDUSTRY",32,"Non-ST Elevation Acute Coronary Syndrome"]